• MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

    Source: Nasdaq GlobeNewswire / 27 Sep 2023 19:00:00   America/New_York

    N/A
Share on,